{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T02:26:44Z","timestamp":1789698404787,"version":"4.0.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.nmd.2026.106411","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:12:02Z","timestamp":1773504722000},"page":"106411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["From case to caution: hyponatremia in a patient with Duchenne muscular dystrophy on vamorolone and lessons for clinicians"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9207-4451","authenticated-orcid":false,"given":"Chelsea","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat","family":"Nasomyont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuixia","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chet","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Reebals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zygmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4142-9527","authenticated-orcid":false,"given":"Meilan M","family":"Rutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.nmd.2026.106411_bib0001","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"10119","key":"10.1016\/j.nmd.2026.106411_bib0002","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study","volume":"391","author":"McDonald","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.nmd.2026.106411_bib0003","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2026.106411_bib0004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3233\/JND-180346","article-title":"Management of adrenal insufficiency risk after long-term systemic glucocorticoid therapy in Duchenne muscular dystrophy: clinical practice recommendations","volume":"6","author":"Bowden","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2026.106411_bib0005","unstructured":"U.S. Food and Drug Administration. FDA vamorolone prescribing information. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215239s000lbl.pdf."},{"key":"10.1016\/j.nmd.2026.106411_bib0006","unstructured":"European Medicines Agency. Agamree: EPAR - product information. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/agamree-epar-product-information_en.pdf."},{"issue":"10","key":"10.1016\/j.nmd.2026.106411_bib0007","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2026.106411_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.nmd.2026.106411_bib0009","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208112","article-title":"Efficacy and safety of vamorolone over 48 weeks in boys with Duchenne muscular dystrophy: a randomized controlled trial","volume":"102","author":"Dang","year":"2024","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.nmd.2026.106411_bib0010","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1210\/clinem\/dgae521","article-title":"Adrenal suppression from vamorolone and prednisone in Duchenne muscular dystrophy: results from the phase 2b clinical trial","volume":"110","author":"Ahmet","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nmd.2026.106411_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2025.109689","article-title":"Mineralocorticoid receptor antagonism of vamorolone: evidence from LIONHEART and VISION-DMD clinical trials","volume":"223","author":"de Vera","year":"2025","journal-title":"Steroids"},{"key":"10.1016\/j.nmd.2026.106411_bib0012","article-title":"Adrenal suppression in Duchenne muscular dystrophy: management strategies incorporating novel steroid vamorolone","author":"Sbrocchi","year":"2025","journal-title":"J Endocr Soc"},{"issue":"2","key":"10.1016\/j.nmd.2026.106411_bib0013","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00246-022-02989-8","article-title":"Early-onset late gadolinium enhancement is a prognostic factor for Duchenne cardiomyopathy","volume":"44","author":"James","year":"2023","journal-title":"Pediatr Cardiol"},{"issue":"13","key":"10.1016\/j.nmd.2026.106411_bib0014","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1161\/CIR.0000000000000526","article-title":"Management of cardiac involvement associated with neuromuscular diseases: a scientific statement from the American Heart Association","volume":"136","author":"Feingold","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.nmd.2026.106411_bib0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.physbeh.2016.12.045","article-title":"Brain mineralocorticoid receptor function in control of salt balance and stress-adaptation","volume":"178","author":"de Kloet","year":"2017","journal-title":"Physiol Behav"},{"issue":"7","key":"10.1016\/j.nmd.2026.106411_bib0016","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1210\/clinem\/dgae250","article-title":"European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: diagnosis and therapy of glucocorticoid-induced adrenal insufficiency","volume":"109","author":"Beuschlein","year":"2024","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626000799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626000799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T02:13:07Z","timestamp":1777342387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896626000799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":16,"alternative-id":["S0960896626000799"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2026.106411","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From case to caution: hyponatremia in a patient with Duchenne muscular dystrophy on vamorolone and lessons for clinicians","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2026.106411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106411"}}